Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | SNCA | P37840 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA5A | P35218 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA3 | P07451 | 1/20 | 0.62 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
| ▸ | CA6 | P23280 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 1/20 | 0.62 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026160 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL14931845 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL2411836 | 0.89 | ALDH1A1 (0.66) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL2411839 | 0.89 | ALDH1A1 (0.66) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL10415000 | 0.89 | ALDH1A1 (0.66) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL10080272 | 0.87 | EPHX2 (0.63) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL17529415 | 0.87 | BACE1 (0.55) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| Hydrochloric Acid SCHEMBL15653104 | 0.87 | ALDH1A1 (0.64) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL8789901 | 0.85 | KDM4E (0.60) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL8789897 | 0.85 | KDM4E (0.60) | KDM4EALDH1A1HPGDHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4748161-A | Triterpenyl esters of organic acids and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1988-05-31 | — | — | US | claimed |
| EP-0166542-A2 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1986-01-02 | — | — | EP | claimed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-12-13 | — | — | US | disclosed |
| US-10093656-B2 | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor | NANJING SANHOME PHARMACEUTICAL CO., LTD (CN) | 2018-10-09 | — | — | US | disclosed |
| EP-3312179-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-25 | — | — | EP | disclosed |
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
| EP-3290419-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-07 | — | — | EP | disclosed |
| EP-3183230-A1 | N-((3,4,5-TRIMETHOXYSTYRYL)ARYL)CINNAMAMIDE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016027282-A1 | N-((3,4,5-TRIMETHOXYSTYRYL)ARYL)CINNAMAMIDE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-02-25 | — | — | WO | disclosed |
| EP-0369627-B1 | Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same | MITSUI TOATSU CHEMICALS (JP) | 1994-12-21 | — | — | EP | disclosed |
| EP-0569380-A1 | ACRIDINE DERIVATIVES. | GLAXO LAB SA (FR) | 1993-11-18 | — | — | EP | disclosed |
| WO-1992012132-A1 | ACRIDINE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1992-07-23 | — | — | WO | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |
| US-5008267-A | Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-04-16 | — | — | US | disclosed |
| EP-0166542-B1 | TRITERPENYL ESTERS OF ORGANIC ACIDS, PROCESS FOR THEIR PRODUCTION, AND HYPOLIPIDEMIC AGENTS COMPOSED OF THEM | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1990-08-08 | — | — | EP | disclosed |
| EP-0369627-A2 | Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-05-23 | — | — | EP | disclosed |
| US-4748161-A | Triterpenyl esters of organic acids and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1988-05-31 | — | — | US | disclosed |
| EP-0166542-A2 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | EGFR, ERBB2, ERBB4 | KDM4E 3193/4885ALDH1A1 3212/4885HPGD 3455/4885 |
| US-10093656-B2 | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor | EGFR, ERBB2, ERBB4 | KDM4E 3193/4885ALDH1A1 3212/4885HPGD 3455/4885 |
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | EGFR, ERBB2, ERBB4 | KDM4E 3193/4885ALDH1A1 3212/4885HPGD 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.